@article{ATM22036,
author = {André J. Scheen},
title = {Effect of sodium-glucose cotransporter type 2 inhibitors on liver fat in patients with type 2 diabetes: hepatic beyond cardiovascular and renal protection?},
journal = {Annals of Translational Medicine},
volume = {6},
number = {Suppl 1},
year = {2018},
keywords = {},
abstract = {Non-alcoholic fatty liver disease (NAFLD) is a common finding in obese people, especially patients with type 2 diabetes (T2DM). It may progress to non-alcoholic steatohepatitis (NASH) and ultimately fibrosis and cirrhosis (1-3). Because of the epidemics of both obesity and T2DM, the prevalence of NAFLD will increase, potentially causing a tremendous clinical and economic burden (4).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/22036}
}